The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Peplin

Status and phase: Withdrawn; Phase 1

Conditions: Warts

Treatments: Drug: PEP005

Study type: Interventional

Funder types: Industry

Identifiers

NCT00546611

PEP005-019

Details and patient eligibility

About

Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact). Common warts have a characteristic cauliflower-like surface, are typically slightly raised above the surrounding skin and are generally diagnosed by visual inspection.The treatment of warts poses a therapeutic challenge for physicians. No single therapy has been proven effective at achieving complete remission in every patient.This study will aim to evaluate an up-to a three-day course of therapy with 0.05% PEP005 Topical Gel.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male and female patients at least 18 years of age.
• A clinically diagnosed, single common cutaneous viral wart (verruca vulgaris) on the dorsal hand.
• Written informed consent has been obtained.
• Agreement from the patient to allow photographs of the common wart(s) treatment area to be taken and used as part of the study package.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

1

Active Comparator group

Description:

Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.

Treatment:

Drug: PEP005